Technology trends reshaping life sciences hiring in 2026

Technology now runs through the daily operating model for most life science companies. It supports research and evidence review, brings more consistency to labs and manufacturing, and is starting to change how patient data gets collected and used.

The defining life sciences technology challenge of 2026 is not adopting the tools but finding the people who can apply them in regulated settings, and those hybrid profiles are now the hardest hires in the market.

Adoption is uneven across the industry, but the direction is clear. Technology is moving closer to the work where mistakes carry the highest cost, including clinical development, quality, manufacturing, regulatory strategy and patient data.

That changes what hiring managers need from their teams. Broad technology experience rarely stands on its own now. A data scientist with no clinical grounding will not get far with datasets that carry regulatory weight, and the same is true of an automation engineer who has never worked to GMP. The people who move the work forward understand how digital tools behave once the setting is scientific, regulated and quality critical.

For hiring managers, that means workforce planning has to move closer to technology strategy, especially where AI, automation, digital trials or connected manufacturing are already changing the work.

 

Life sciences technology trends gaining momentum in 2026

The trends gaining momentum are not always the newest technologies. They are the ones moving out of pilots, innovation teams and isolated use cases into wider operational settings.

Trend	Where it is showing up	What hiring managers should watch
1. AI in development decisions	R&D, diagnostics, trial planning, evidence review and clinical data	People who understand both data outputs and scientific, clinical or regulatory context
2. Automation and robotics	Labs, diagnostics, QC, testing and manufacturing support	Workflow design, implementation, validation and lab informatics experience
3. Digital trials	Remote monitoring, decentralized models and patient-generated data	Clinical operations and data teams with digital trial experience
4. Real-world evidence	Regulatory, payer, medical and post-market work	RWE, HEOR, epidemiology, biostatistics and data governance capability
5. Manufacturing technology	Advanced therapies, diagnostics, medical devices and complex products	MSAT, CMC, validation, quality, process development and inspection readiness
6. Cybersecurity and data infrastructure	Patient data, IP, cloud platforms, connected devices and manufacturing systems	Cybersecurity, cloud, CSV/CSA and supplier risk experience

 

1. AI is moving into development decision-making

AI is now close enough to core life sciences work that the conversation has become more practical. It is being used to support target identification, disease modeling, diagnostics, imaging, evidence review, trial planning and clinical data analysis.

The value is clearest when teams are working with large, complex datasets. AI can help identify patterns earlier and reduce some of the manual work behind research and development decisions. The risk is overconfidence. A model can produce a convincing output from incomplete data, weak assumptions or a poorly framed question.

Life sciences teams still need people who can look beyond the output and understand the data behind it, the limitations of the model and the consequences of using that result in a regulated setting.

Regulators across major markets are already paying closer attention. The FDA has issued draft guidance on AI used to support regulatory decision-making for drugs and biological products and the EMA has published a reflection paper on the use of AI across the medicinal product lifecycle.

In the UK, the MHRA runs a dedicated software and AI as a medical device program, including the AI Airlock sandbox, with an AI-specific framework expected in 2026. The common thread is a demand for AI-generated evidence that is reliable, controlled and appropriate for the decision being made.

For hiring managers, this changes the profile of AI-related hiring. The strongest candidates are not always traditional technology hires. The harder people to find are often computational biologists, bioinformatics specialists, clinical data leaders, translational scientists and the regulatory or quality professionals who understand how AI is actually being applied inside life sciences work.

Deloitte’s 2026 life sciences and healthcare technology report found that 30% of life sciences leaders cite a significant strategic impact from agentic AI, while only 22% say they have successfully scaled AI, and just 9% report achieving significant returns. That gap reflects where many organizations are now. They are interested and active, but still working out how to scale AI safely in regulated environments.

For a deeper look at how AI agents are being applied across discovery, clinical development, regulatory work and manufacturing, read our article on agentic AI in life sciences.

 

2. Automation is exposing manual workflow gaps

Automation and robotics are becoming more relevant across life sciences because many teams are still managing complex work through manual processes. That is especially visible in labs, diagnostics, quality control and manufacturing support, where pressure to increase throughput often sits alongside strict requirements for accuracy, traceability and consistency.

In research settings, automation can support sample handling, high-throughput screening, assay workflows and data capture. In diagnostics and testing environments, it can help teams manage volume without losing reliability. In manufacturing and quality environments, automation can reduce documentation burden, improve process visibility and support more consistent execution.

The reason this trend matters in 2026 is not that every life sciences company is suddenly building a fully automated lab. Most are not. The more immediate shift is that automation is moving into routine workflows where manual variation slows teams down or creates avoidable risk.

The risk is assuming automation will tidy up a process that has not been properly defined. In practice, it often does the opposite. If a workflow is inconsistent, poorly documented or difficult to validate, automation can make those gaps more visible, creating new issues around validation, change control, data integrity or ownership of the system.

This makes automation a capability issue, not an equipment or software decision. Companies need people who understand the scientific workflow, work with technical teams and operate within quality expectations. That means automation engineers, lab informatics specialists, validation professionals, robotics specialists and quality systems experts. The candidates who succeed are rarely the ones most comfortable with the equipment. They are the ones who ask what the process is meant to do before anyone automates it.

 

3. Digital trials are changing how patient data is collected

Digital trials are gaining traction because clinical development still has a practical problem. Recruiting, monitoring and retaining patients is difficult, expensive and often slow. Remote monitoring, decentralized elements and digital health technologies can make participation easier for some patients and give sponsors more flexibility in how data is collected.

The FDA has issued guidance on digital health technologies for remote data acquisition in clinical investigations, giving recommendations on how these tools can be used to collect data from trial participants outside traditional settings.

This does not make trial design simpler. Digital data still needs to be accurate, consistent and usable. If a trial collects more patient-generated data but cannot connect it clearly to endpoints, site workflows or regulatory expectations, the technology adds work rather than reducing it.

The impact reaches data management, biostatistics, regulatory strategy, medical affairs and market access. The pressure sits on people who understand both trial execution and data quality. That includes clinical operations professionals with decentralized trial experience, clinical data leaders, biostatisticians and project leaders. Digital trial tools rarely create value on their own. They need teams who can turn patient-generated data into evidence that is usable, reliable and aligned with regulatory expectations.

 

4. Real-world evidence is becoming harder to ignore

Real-world evidence has moved well beyond post-launch monitoring. It is now part of how life sciences companies think about access, safety, effectiveness, product value and long-term market performance.
Traditional clinical trials remain essential, but they do not answer every question companies, regulators, payers, providers or patients have about how a product performs in practice. Real-world data can help fill some of that gap, using sources such as electronic health records, claims data, registries and digital health technologies.

The FDA defines real-world evidence as clinical evidence about the use, benefits or risks of a medical product derived from real-world data. It also notes that advances in the availability and analysis of real-world data have increased the potential for RWE to support regulatory decisions.

Credibility is the whole game with RWE. Poorly governed data does not support better decisions just because there is more of it. The teams doing this well are usually thinking carefully about data quality, bias, patient populations, endpoint relevance and how the evidence will be used by different stakeholders.

RWE now touches clinical development, regulatory strategy, medical affairs, HEOR, market access and post-market surveillance, which means teams need both data capability and context around how that evidence will be used.

For hiring managers, the challenge is finding people who can make evidence usable, not just analyze data. That means stronger demand for RWE leaders, HEOR specialists, epidemiologists, biostatisticians and data governance professionals who understand how evidence will be judged by regulators, payers and internal decision-makers.

 

5. Manufacturing technology is moving up the priority list

Manufacturing often gets left out of life sciences technology conversations, but it is one of the clearest places where technology affects delivery.

Biologics, advanced therapies, diagnostics, medical devices and complex drug products all rely on processes that need to be controlled, documented and scaled without compromising quality. As products become more complex, manufacturing teams need better visibility across process data, quality systems, validation, technology transfer and supply continuity.

Connected quality systems, digital batch records, process analytics and manufacturing automation can help teams identify issues earlier and manage production with more control. They can also expose existing weaknesses where data is fragmented, documentation is inconsistent or ownership is unclear.

Fast-growing markets such as GLP-1s show how quickly manufacturing demand can become a talent issue. When production needs to scale at speed, pressure builds across quality, regulatory, supply chain and manufacturing teams at the same time. Companies need the technology to manage that complexity, but they also need people who understand validation, GMP expectations, process control and inspection readiness.

The talent impact is visible in MSAT, CMC, process development, validation, GMP quality and manufacturing systems. We see this most clearly in fill-finish and MSAT hiring tied to GLP-1 scale-up, where several critical roles often open at once and compete for the same small pool of inspection-ready candidates. When that happens the constraint is rarely the technology. It is the number of people who have done it before.

For drug developers, this connects closely to CMC in drug development, where manufacturing, analytical controls and regulatory evidence determine whether a product can progress safely and consistently.

 

6. Data infrastructure and cybersecurity are becoming operational risks

AI, digital trials, real-world evidence and connected manufacturing all depend on data that is accurate, accessible, traceable and protected. If clinical data is fragmented, manufacturing data is difficult to trace or quality records sit across disconnected systems, teams will struggle to use technology properly.

Cybersecurity carries a different level of risk in life sciences because companies are protecting patient data, clinical trial information, intellectual property, manufacturing systems and regulatory documentation. A cyber incident can disrupt trials, delay manufacturing, expose sensitive information or weaken confidence with partners, regulators and patients.

As companies use more cloud platforms, connected devices, third-party vendors, digital health tools and external data partnerships, supplier risk, access controls and data governance become more important. This points to growing demand for cybersecurity, cloud, data governance and CSV/CSA expertise. The qualifier that matters is regulated industry experience. A strong security professional from another sector does not automatically understand data integrity, audit trails or what an inspector will ask for. In life sciences that context is the job, not an add-on.

 

What these trends mean for life sciences hiring

The common thread across these technology trends is capability. Life sciences companies are changing the skills needed across research, clinical development, manufacturing, quality, regulatory, commercial and corporate functions.

The difficult roles are often the ones that sit between disciplines. A quality leader who can work with connected manufacturing systems. A clinical operations specialist who has managed decentralized studies. A regulatory professional who can hold AI-generated evidence to the right standard. Regulatory and quality expertise also needs to be involved earlier, especially where AI, digital trial tools or manufacturing technology affect evidence, documentation or inspection readiness.

These profiles are harder to find because they do not always sit neatly in one function. They may also be embedded in critical projects and unlikely to respond to a standard job advert. The strongest hiring strategies identify where technology is changing the work itself, then decide whether permanent leadership, project-based specialists, contract support or a blend of all three is needed.

 

Building technology capability in life sciences

The companies that handle this well treat it as a hiring problem early, before the technology exposes the gap.

EPM Scientific supports life sciences organizations with specialist talent across research and development, clinical, manufacturing, quality, regulatory, commercial and corporate functions. If your organization is building teams to support technology adoption, transformation or growth, our consultants can help you understand the market and secure the expertise needed to move forward.

Request a call back

Submit a vacancy